文献速递胸部肿瘤

国际肺癌研究协会对接受新辅助治疗后的切除肺癌病理缓解评估的可重复性研究

International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
PubMed 文献 · J Thorac Oncol · 2023-09-12

国际肺癌研究协会(IASLC)组织11名肺部病理学家,对6项临床试验中84例接受新辅助免疫检查点抑制剂后切除的NSCLC肿瘤HE染色切片进行病理缓解评估。结果显示,81%(68例)的患者在主要病理缓解(MPR)上获得病理学家一致同意,未加权和加权平均的评分者间一致性分别为0.84(95%CI 0.76-0.92)和0.86(95%CI 0.79-0.93)。

要点

  • 81%(68例)患者MPR评估获得全部病理学家一致同意
  • 未加权与加权平均MPR的评分者间一致性分别为0.84和0.86
  • 无残留存活肿瘤病例一致性最高(IRA=0.94),>95%存活肿瘤病例IRA=0.98

核心结论

  • IASLC推荐的存活肿瘤≤10%切点用于新辅助治疗后MPR评估具有良好可靠性,无残留存活肿瘤病例可靠性极好。

研究设计与样本

  • 国际小组由11名肺部病理学家组成,回顾性评估84例接受新辅助免疫检查点抑制剂后切除的NSCLC肿瘤HE染色切片,来自6项临床试验。
  • 对每张切片镜下测量瘤床面积,用预嵌入公式计算未加权和加权MPR平均值以反映不同瘤床比例。

主要发现

  • 68例(81%)患者MPR获得病理学家一致同意。
  • 未加权平均MPR的评分者间一致性为0.84(95%CI 0.76-0.92),加权平均为0.86(95%CI 0.79-0.93)。
  • 未加权与加权方法在MPR分类上未显示显著差异。
  • 存活肿瘤>95%病例的IRA=0.98(95%CI 0.96-1),0%存活肿瘤病例的IRA=0.94(95%CI 0.89-0.98),为两种方法下一致性最高的情形。

关键数值与推荐

  • MPR定义为存活肿瘤≤10%(IASLC推荐切点)。
  • 不一致最常见原因包括:瘤床判读、显著间质炎症、反应性 versus 肿瘤性肺泡上皮细胞鉴别、浸润性黏液腺癌评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pathologic response has been proposed as an early clinical trial end point of survival after neoadjuvant treatment in clinical trials of NSCLC. The International Association for the Study of Lung Cancer (IASLC) published recommendations for pathologic evaluation of resected lung cancers after neoadjuvant therapy. The aim of this study was to assess pathologic response interobserver reproducibility using IASLC criteria. METHODS: An international panel of 11 pulmonary pathologists reviewed hematoxylin and eosin-stained slides from the lung tumors of resected NSCLC from 84 patients who received neoadjuvant immune checkpoint inhibitors in six clinical trials. Pathologic response was assessed for percent viable tumor, necrosis, and stroma. For each slide, tumor bed area was measured microscopically, and pre-embedded formulas calculated unweighted and weighted major pathologic response (MPR) averages to reflect variable tumor bed proportion. RESULTS: Unanimous agreement among pathologists for MPR was observed in 68 patients (81%), and inter-rater agreement (IRA) was 0.84 (95% confidence interval [CI]: 0.76-0.92) and 0.86 (95% CI: 0.79-0.93) for unweighted and weighted averages, respectively. Overall, unweighted and weighted methods did not reveal significant differences in the classification of MPR. The highest concordance by both methods was observed for cases with more than 95% viable tumor (IRA = 0.98, 95% CI: 0.96-1) and 0% viable tumor (IRA = 0.94, 95% CI: 0.89-0.98). The most common reasons for discrepancies included interpretations of tumor bed, presence of prominent stromal inflammation, distinction between reactive and neoplastic pneumocytes, and assessment of invasive mucinous adenocarcinoma. CONCLUSIONS: Our study revealed excellent reliability in cases with no residual viable tumor and good reliability for MPR with the IASLC recommended less than or equal to 10% cutoff for viable tumor after neoadjuvant therapy.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Dacic S, Travis W, Redman M, et al. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. J Thorac Oncol. 2023. PMID: 37702631. doi:10.1016/j.jtho.2023.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。